Echocardiography, Exercise, Healthy Volunteers, Inflammation, Oxidative Stress, Physical Fitness
Conditions
Brief summary
Regular aerobic exercise may improve cardiorespiratory fitness while modulating systemic inflammation and oxidative stress. Spinning, as a structured indoor cycling modality, provides a practical aerobic exercise model with adjustable intensity and duration, but its effects on redox balance, inflammatory status, aerobic capacity, and cardiac functional parameters may vary according to individual recovery and nutritional status. Magnesium is an essential micronutrient involved in energy metabolism, muscle contraction-relaxation, ion regulation, and inflammatory and oxidative pathways; therefore, magnesium use may be relevant to exercise adaptation and recovery. This study aims to evaluate the associations of magnesium use and spinning training with oxidative stress, inflammation, aerobic capacity, and cardiac parameters. In this context, biochemical markers related to oxidative/antioxidant status and inflammation, aerobic performance indicators, and echocardiographic cardiac function parameters will be assessed together. The study is expected to provide real-world evidence on whether magnesium use in individuals participating in spinning training is associated with more favorable redox, inflammatory, aerobic, and cardiac profiles.
Interventions
BEHAVIORALSpinning Training
Participants will participate in a structured spinning training program during the study period. The program will consist of supervised indoor cycling sessions performed at a planned frequency, duration, and intensity.
DIETARY_SUPPLEMENTMagnesium Supplementation
Participants will receive oral magnesium supplementation during the study period in addition to the structured spinning training program.
Sponsors
Karamanoğlu Mehmetbey University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Self-identified male participants * Aged 18 to 30 years * Physically active individuals * Participants who are eligible to participate in a structured spinning training program * Participants with available baseline and follow-up assessments for biochemical, aerobic capacity, and cardiac function parameters
Exclusion criteria
* Presence of any chronic systemic disease * Acute infection during the study period * Regular use of anti-inflammatory or antioxidant medications * Use of antioxidant or ergogenic supplements other than magnesium * Any cardiovascular, musculoskeletal, or neurological condition that may limit participation in spinning training * Missing baseline or follow-up outcome data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Maximal Oxygen Uptake (VO₂max) | Baseline and 6 weeks | Maximal oxygen uptake (VO₂max, mL/kg/min) will be assessed using a graded exercise test. The change in VO₂max from baseline to 6 weeks will be evaluated. |
| Change in Serum Magnesium Concentration | Baseline and 6 weeks | Serum magnesium concentration (mg/dL) will be measured using standard laboratory methods. The change in serum magnesium levels from baseline to 6 weeks will be evaluated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Total Antioxidant Status (TAS) | Baseline and 6 weeks | Serum total antioxidant status (TAS, mmol Trolox equivalent/L) will be measured using commercially available assay kits. The change in TAS from baseline to 6 weeks will be evaluated. |
| Change in Total Oxidant Status (TOS) | Baseline and 6 weeks | Serum total oxidant status (TOS, μmol H₂O₂ equivalent/L) will be measured using commercially available assay kits. The change in TOS from baseline to 6 weeks will be evaluated. |
| Change in Paraoxonase-1 Activity (PON1) | Baseline and 6 weeks | Serum paraoxonase-1 (PON1, U/L) activity will be determined using spectrophotometric methods. The change in PON1 activity from baseline to 6 weeks will be evaluated. |
| Change in Arylesterase Activity (ARE) | Baseline and 6 weeks | Serum arylesterase (ARE, kU/L) activity will be determined using spectrophotometric methods. The change in ARE activity from baseline to 6 weeks will be evaluated. |
| Change in High-Sensitivity C-Reactive Protein (hs-CRP) | Baseline and 6 weeks | Serum high-sensitivity C-reactive protein (hs-CRP, mg/L) concentration will be measured using standard laboratory methods. The change in hs-CRP levels from baseline to 6 weeks will be evaluated. |
| Change in Interleukin-6 (IL-6) | Baseline and 6 weeks | Serum interleukin-6 (IL-6, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods. The change in IL-6 levels from baseline to 6 weeks will be evaluated. |
| Change in Tumor Necrosis Factor-Alpha (TNF-α) | Baseline and 6 weeks | Serum tumor necrosis factor-alpha (TNF-α, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods. The change in TNF-α levels from baseline to 6 weeks will be evaluated. |
| Change in Serum Potassium Concentration | Baseline and 6 weeks | Serum potassium concentration (mmol/L) will be measured using standard biochemical methods. The change in serum potassium levels from baseline to 6 weeks will be evaluated. |
| Change in Serum Calcium Concentration | Baseline and 6 weeks | Serum calcium concentration (mg/dL) will be measured using standard biochemical methods. The change in serum calcium levels from baseline to 6 weeks will be evaluated. |
| Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) | Baseline and 6 weeks | Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP, pg/mL) concentration will be measured using immunoassay methods. The change in NT-proBNP levels from baseline to 6 weeks will be evaluated. |
| Change in Left Ventricular Ejection Fraction (LVEF) | Baseline and 6 weeks | Left ventricular ejection fraction (LVEF, %) will be assessed by transthoracic echocardiography. The change in LVEF from baseline to 6 weeks will be evaluated. |
Countries
Turkey (Türkiye)
Contacts
PRINCIPAL_INVESTIGATORŞemsi Gül Yılmaz Kocaman, PhD
Karamanoğlu Mehmetbey University
Outcome results
None listed